Invion (ASX:IVX)
ASX announcement history & article coverage
Transparent by design.
Announcments by Invion (ASX:IVX) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Photosoft and Novel Immunotherapy Collaboration Partnership
Recruitment Conclusion for Ph 1 NMSC Trial & Advance to Ph 2
Invion completes INV043 skin cancer Phase I trial recruitment and plans Phase II after positive preliminary safety and efficacy findings
Application for quotation of securities - IVX
Proposed issue of securities - IVX
Director Loans
Appendix 4G and Corporate Governance Statement
Appendix 4E and Annual Report
Invion Limited reports FY2026 loss of $5.63M, advances PhotosoftTM licensing and clinical programs
Initial Director's Interest Notice - Paul FIeld
Final Director's Interest Notice - Alistair Bennallack
IVX Credentialed International Biotech Leader Joins Board
Appendix 4C and Quarterly Activities Report - June 2026